The brains of rats and humans express the enzymes required for the synthesis of aldosterone from cholesterol, including the 3 -steroid dehydrogenase that catalyzes the conversion of pregnenolone to progesterone in the pathway of adrenal steroid synthesis. Salt-induced hypertension in the Dahl SS/jr rat is associated with normal to low levels of circulating aldosterone, yet it is abrogated by the central infusion of mineralocorticoid receptor antagonists. To test the hypothesis that de novo synthesis of aldosterone in the brain has a pathophysiological role in the salt-induced hypertension of the SS rat, the 3 -steroid dehydrogenase antagonist trilostane was infused continuously intracerebroventricularly or subcutaneously in two different cohorts of Dahl SS/jr rats, one female, the other male, during and after the development of salt-induced hypertension. The doses of trilostane used had no effect on blood pressure when infused subcutaneously. Animals receiving vehicle icv experienced a 30-45mmHg increase in systolic blood pressure measured by tail cuff. The intracerebroventricular, but not subcutaneous, infusion of 0.3µg/h trilostane effectively blocked the increase in systolic blood pressure and reversed the hypertension produced by drinking 0.9% saline. Trilostane was equally effective in female and male rats. Weight gain, serum aldosterone and corticosterone concentrations, and behavior assessed subjectively and by elevated plus maze, were unchanged by the trilostane treatment. These studies suggest that the synthesis in the brain of a mineralocorticoid receptor agonist, probably aldosterone, is responsible in part for the salt induced hypertension of the inbred Dahl SS/jr rat.
Introduction
All of the enzymes required for the synthesis of adrenal corticosteroids from cholesterol are expressed in specific anatomical areas of the rat brain, albeit in very small amounts (7, 12, 31, 32) . The mRNAs for these enzymes have also been demonstrated in human brain (46) . In addition, ancillary proteins required for de novo synthesis of adrenal steroids, StAR protein, adrenodoxin and adrenodoxin reductase, are also expressed in the brain (7, 8, 26, 33, 39) . Aldosterone, corticosterone and 18-hydroxycorticosterone are synthesized by minces of specific regions of brains from adrenalectomized rats from endogenous substrates and exogenous tritiated precursors (12, 13). The amount of corticosteroid biosynthesis by brain tissue in vitro is exceedingly small, even when exogenous substrates are provided, and circulating aldosterone and corticosterone in plasma are undetectable in the adrenalectomized individual. Therefore the in vivo activity of these steroids, if any, must be local, either paracrine or autocrine.
Aldosterone synthesis within the brain may be important in the development of hypertension in the inbred Dahl Salt Sensitive (SS/jr) rat. The SS/jr are spontaneously hypertensive on a normal, 0.3% NaCl diet, but salt challenge greatly accelerates the development and increases the amplitude of the hypertension. We and others have found that plasma levels of aldosterone of the SS/jr rats are normal, and lowered further by a high salt diet (1) . Activation of mineralocorticoid receptors (MR) within the brain is responsible in great measure for the salt-induced increase in blood pressure, as the central infusions of MR antagonists at doses that have no effect systemically block the hypertension in the SS/jr rat (18). The central effect of MR activation, like that in epithelial cells of the kidney and colon, includes the increase in epithelial sodium channel (ENaC) activity. Salt-induced hypertension in the SS/jr rat is also blocked by the icv infusion of an ENaC selective amiloride, benzamil, at doses lower than that required to lower the blood pressure systemically (21). This sensitivity to antagonists of aldosterone action even though circulating aldosterone concentrations are not elevated may be analogous to that seen in patients with low renin essential hypertension who respond to anti-mineralocorticoid therapy with spironolactone or amiloride, even though their aldosterone levels are not elevated (4) . The salt-induced hypertension in the SS/jr is partially inhibited by the chronic intracerebroventricular infusion of 19-ethynyl DOC, a suicide inhibitor of the aldosterone synthase, at a dose that had no effect when infused systemically (12). However, 19-ethynyl DOC is a partial agonist and its toxicity limits studies of aldosterone synthase (8) .
Cholesterol is successively converted to pregnenolone, then progesterone, and 11-deoxycorticosterone (DOC) by the sequential actions of the cytochrome P450 side chain cleavage, 3ß-hydroxysteroid dehydrogenase/isomerase (3 -HSD), and cytochrome P-450 21 enzymes, respectively. DOC is converted to corticosterone by cytochrome P450-11ß-hydroxylase (CYP11B1) and by a series of hydroxylations to aldosterone by cytochrome P450-aldosterone synthase (CYP11B2). The predominant neurosteroids are GABA A receptor-modulating derivatives produced from pregnenolone and progesterone through the action of the 5alpha-reductase-3alpha-hydroxysteroid enzyme complex (30, 38) . The CYP-21 hydroxylase, which produces DOC from progesterone, and 11ß-hydroxylase and aldosterone synthase which use DOC as substrate, are expressed in very low amounts in the brain (46, 47) . The expression of the CYP-21 hydroxylase was in question before methods to detect very low levels were developed (12, 34) and it appears that the cytochrome P450-2D4 is the most likely enzyme to catalyze the 21-hydroxylation in the brain (27) . Trilostane is an inhibitor of 3 -hydroxysteroid dehydrogenase that was developed as an adrenal steroid synthesis inhibitor and has been used for almost 30 years to study adrenal, gonadal and neurosteroid synthesis and metabolism and physiological activity, as well as the treatment of Cushings syndrome, adrenal adenomas and breast cancer (6, 25) (41).
Trilostane does not have mineralocorticoid receptor antagonistic activity (24) (41).
Some neurosteroids derived from progesterone modulate GABA A receptors and decrease seizure threshold. Extrapolating from toxicology data, we selected doses of trilostane that would decrease progesterone levels and its derivatives, but not to levels that caused seizures (28, 37, 45) . The intent was to reduce the amount of progesterone available for the formation of DOC, the precursor for aldosterone and corticosterone and a mineralocorticoid itself, to a level below that which allowed the production of enough aldosterone to inappropriately activate the MR in the brain responsible for the hypertension in the Dahl SS rat. We are reporting the effect of the chronic intracerebroventricular infusion of trilostane, an inhibitor of the 3 -hydroxysteroid dehydrogenase, on the blood pressure of SS rats challenged with a high salt diet.
Materials and Methods
Animal subjects: These studies were carried out in young adult female and male Trilostane (2 -cyano-4 ,5 -epoxyandrostan-17 -ol-3-one; Sanofi, Malverne, PA) was dissolved in 45% 2-hydroxypropyl -cyclodextrin in a proportion of 1:2, trilostane: cyclodextrin, molar ratio (RBI, Natick, MA) then diluted to 5% -cyclodextrin with saline. The control solution was 5% -cyclodextrin. Placement of the intracerebroventricular (icv) cannulae and pumps was as described previously (16). The doses were calculated from previous reports to partially block the 3--hydroxysteroid dehydrogenase (45) .
For the experiment with the female rats, 14-day mini-osmotic pumps (Alza Corp, Palo Alto, CA) delivering 0.48 µl/h were used to deliver either 0.1 or 0.3µg/hr of trilostane icv and changed every 13-14 days. At 6 weeks, at the time of the third pump change, the pumps of the animals receiving 0.1 µg/hr were switched to deliver 0.3 µg/hr. The pumps in the group receiving 0.3 µg/hr were switched to vehicle. For the experiment with the males, 28-day pumps delivering 0.25 µl/h were used. Two groups received vehicle icv, one group received 0.3 µg/hr icv, and one group received 0.3 µg/hr sc. At 3.5 weeks the pumps were changed. The pump content of one of the vehicle icv groups was changed to deliver 0.3 µg/hr icv; the rest of animals continued to receive the original infusions.
Systolic blood Pressure was measured by tail-cuff plethysmography in trained unheated animals between 8-12:00 am, 2-3 times a week. To minimize stress, no animal was restrained for more than 10 minutes at a time. If a rat did not become settled immediately after entering the tube, it was allowed cage time before trying to measure the pressure again. The time that it took the rat to settle in its tube and relax its tail was noted and used as a subjective measure of anxiety. Body weight was recorded after each blood pressure measurement.
Elevated plus maze was originally designed to assess anxiety, but also allows easy observation of ataxia, tremors or other motor or behavioral abnormalities (2, 43) . The apparatus comprises 4 connecting limbs, each 50 cm long X 10 cm wide, in the shape of a "+", 2 limbs with, and 2 without, 10 cm side walls. The rat was placed in the center and allowed to explore for 5 minutes. It was scored by recording the total distance in cm that it traveled, with travel in the sideless arms weighted by multiplying by 2. The more anxious and fearful, the less distance will be traveled, especially in the sideless arms of the apparatus. The number of times that the rat urinates or defecates also correlates positively with anxiety (2, 43) . The females were observed on the maze 3 times, once before the experiment started, just before the crossover in treatment, and at the end of the experiment. The males were tested once, near the end of the experiment, to avoid a training bias.
The week before the end of the experiment, the male rats were placed in stainless steel rat metabolism cages for 3 days of an acclimatization period, followed by 3 consecutive 24 h urine collections. Urine albumin, aldosterone and corticosterone were measured and normalized as a ratio to creatinine.
Tissue collection: The rats were mask-induced with isoflurane delivered in oxygen with a standard anesthesia machine, 4-5ml blood was drawn from the left ventricle into an EDTA vacutainer, the aorta was cut, draining blood from the brain, and brain removed and frozen in liquid nitrogen within 4-6 minutes of the rat being taken from its cage.
Aldosterone and corticosterone assays in plasma, urine and brain: These steroids were measured in plasma and urine as we have previously described (10, 20, 35, 36).
The brain was weighed and 5 ml of water was added containing 2000 cpm of tritiated aldosterone for estimation of recoveries. It was then homogenized and extracted with 25 ml of dichloromethane. The sample was cleaned by passing the dichloromethane through a silica gel column (Silica Gel Grade 62 from Sigma-Aldrich, St Louis, MO) pre washed with 5 ml of dichloromethane, where the steroids were adsorbed. The steroids were then eluted with 5 ml of dichloromethane containing 7% methanol. The organic extract was then evaporated in a Vortex Evaporator, reconstituted and assayed using an ELISA buffer (sodium phosphate 20mM, sodium chloride 100 mM, thimerosal 0.01 % and Tween 20 0.05%). The sensitivity of the ELISA for aldosterone was 1 pg/well and for corticosterone 10 pg/well. Results are expressed as pg/g (aldosterone) or ng/g (corticosterone) of tissue, pg/ml and ng/ml, respectively in plasma.
Urine albumin was measured by ELISA using a sheep antibody raised against rat albumin produced in house. Urine creatinine was measured by the standard picric acid method.
Differences between groups were evaluated by ANOVA, followed by a Fisher LSD or Tukey contrast where appropriate (STATISTICA 6.0; StatSoft package). Results are expressed as the mean ± SEM.
Results
The experiment with female rats comprised 3 groups with an n=5: vehicle icv, trilostane 0.1 µg/hour icv, and trilostane 0.3 µg/hour icv. The dose of 0.3µg/hr, but not 0.1µg/hr, icv blocked the rise in blood pressure produced by drinking 0.9% saline (Fig   1) . At 4 weeks of treatment the pressures of rats receiving 0.1µg/h trilostane icv were no different than those receiving the vehicle icv, an increase of about 30mmHg from a pretreatment baseline average systolic blood pressure of 120 mmHg . After 4 weeks the pump solutions were changed so that the rats that had been receiving 0.1µg/hr trilostane icv, received 0.3µg/hr icv, and those receiving 0.3µg/hr trilostane icv, received vehicle. The pressures of the former decreased significantly within 1 week and stayed low until the pumps ran out 4 weeks later, 8 weeks into the experiment, at which time they again increased to the level of the controls. Blood pressures of the female rats started on 0.3µg/hr trilostane, then switched to vehicle icv, increased to control levels within a week of changing their treatment to the vehicle.
There was no difference in weight gain between the groups of females throughout the experiment, nor was there a difference in tibia length, the weights of the kidneys, adrenal glands, or hearts, or the ratio of the heart to body weight at the end of the experiment. Their weight increased from 200.1g ± 2.1 at 11 weeks, to 255.3 ± 3.5 at 19 weeks of age. Similarly, there were no differences in weight gain between the groups of male rats. Behavior assessed subjectively, as well as by elevated plus maze, was not altered by these doses of trilostane.
There were 4 groups, n=8, in the experiment with males ( Figure 2 ): vehicle icv; vehicle icv 3.5 weeks, followed by 0.3µg/hr trilostane icv; 0.3µg/hr trilostane icv; and vehicle icv + 0.3µg/hr trilostane sc. The pre-treatment mean systolic blood pressures for all rats was 139.7 ± 3.8 mmHg. Within 3.5 weeks of a high salt intake the two groups receiving vehicle icv and the group receiving vehicle icv + 0.3µg/hr trilostane sc had similar increases in blood pressure to 164 ± 3.6, 159 ± 8.6 and 158 ± 3.1, respectively, while the pressures of the rats receiving 0.3µg/hr trilostane icv remained at baseline.
The pumps were replaced with pumps delivering the original solution except for those in the second vehicle icv group; these were switched to 0.3µg/hr trilostane icv. Within a week the pressures of these rats decreased to the level of those receiving 0.3µg/hr trilostane icv from the beginning, while the pressures of the vehicle and vehicle icv + 0.3µg/hr trilostane sc groups continued to increase slowly. Three and a half weeks after the second pumps were implanted, the systolic blood pressures were 176 ± 1.1 and 174.5 ± 2.3 for the icv vehicle and trilostane sc groups and 136.3 ± 2.6 and 140.3 ± 4.7 for the two groups receiving trilostane icv. All rats gained weight at the same constant rate, starting at 309.2 ± 5.25 at 11 weeks, reaching 418.8 ± 5.8 g at 19 weeks of age.
There were no significant differences between groups in or plasma or brain aldosterone or corticosterone concentrations or in urine albumin or aldosterone normalized to creatinine excretion. Behavior assessed subjectively, as well as by elevated plus maze, was not altered by treatment with trilostane.
Discussion
Trilostane is an inhibitor of the 3 -hydroxysteroid dehydrogenase responsible for the conversion of pregnenolone to progesterone. The doses chosen for this study were 3 orders of magnitude below the reported seizure ED50 for mice, with the postulate that enough progesterone would still be formed to maintain normal neuronal excitability (45) , but the formation of DOC and the subsequent steroids in the cascade would be below the amount required to elevate the blood pressure upon salt challenge in these Dahl SS rats. The central infusion of 0.3µg/hr trilostane icv consistently decreased systolic blood pressure in both female and male rats in separate experiments without altering the rate of growth, behavior or gross motor ability. As growth and behavior were not altered by the dose of trilostane that prevented the salt-induced increase in blood pressure in the Dahl SS rats, it is assumed that enough of the GABAergic modulating neurosteroid derivatives of progesterone remained to sustain a normal life and that the effects seen on the blood pressure were not due to generalized weakness or poor health.
The elevated + maze has been used successfully to follow corticosterone and hippocampal MR-induced behavioral responses (2) and was used in these experiments to assess effects of the trilostane infusions on activity, anxiety and motor abilities. Our results suggest that while trilostane reached the circumventricular organs in effective inhibitory amounts, at the icv infusion rate of 0.3 µg/hr it either did not diffuse in relevant amounts to the hippocampus, or aldosterone or corticosterone synthesis in the hippocampus is not very important for those parameters assessed.
The mineralocorticoid receptor (MR) is abundantly and widely expressed within the brain. In normotensive Sprague-Dawley or Wistar rats, the chronic intracerebroventricular (icv) infusion of as little as 5ng/hr aldosterone, but not corticosterone, produces hypertension of the same rate of onset and amplitude as 500ng/hr aldosterone infused subcutaneously (23). The icv infusion of an MR antagonist prevents the hypertension produced by the systemic infusion of aldosterone in genetically normotensive rats and by salt challenge in the Dahl SS/jr rat even though circulating aldosterone levels in the latter are not very elevated (15, 19). These and ablation studies suggest that MR in the circumventricular organs, particularly those of the hypothalamus, mediate mMR effects on the blood pressure (3, 9, 14, 15). Absolute plasma levels of aldosterone must be interpreted considering physiological need. A high salt diet suppresses adrenal production of aldosterone. In the present experiments, the rats consumed a high salt diet and aldosterone was suppressed compared to rats on a low or normal salt diet (17), however their response to MR antagonists when salt-challenged indicates that suppression of aldosterone synthesis is not adequate. Little in known about the regulation of aldosterone synthesis in the brain, but the brain renin angiotensin system, rather than the renal or systemic RAAS, and sodium sensors in the central nervous system are the most promising candidates (44) (42) The MR binds corticosterone, cortisol, aldosterone and progesterone with similar affinity. Co-expression of 11 -hydroxysteroid dehydrogenase 2 enzyme, that inactivates corticosterone or cortisol, with the MR allows aldosterone to access the MR despite a ratio of less than 1:100 circulating aldosterone:corticosterone.
Where there is little or no 11-HSD2, for example the hippocampus, the MR is occupied by glucocorticoids. The amount and distribution in the brain of 11-HSD2 enzyme is also reported to be inadequate to protect MR in the circumventricular organs of the anterior hypothalamus (40) . Aldosterone synthase immunoreactivity is found in these areas (unpublished), as well as in the hippocampus and cerebellum (29) . Synthesis of aldosterone in or near cells expressing MR would increase the ratio of aldosterone to corticosterone concentrations just as destruction of corticosterone would (11, 22) .
We speculate that de novo synthesis of aldosterone within circumventricular organs thought to be involved in salt sensitive and mineralocorticoid hypertension (15) (9) is responsible for mediating the blood pressure increase in the Dahl SS rat and that trilostane infused icv at 0.3 µg/hr partially inhibited the 3 -hydroxysteroid dehydrogenase the circumventricular organs, decreasing the amount of progesterone available for the production of DOC and aldosterone to levels below that which elevates the pressure in the salt-challenged Dahl SS rats. Trilostane is not an antagonist of the mineralocorticoid receptor (24) . A decrease in plasma and brain aldosterone and corticosterone content in the rats receiving trilostane was not detected. The dose of trilostane was well below the effective systemic dose, so a decrease in adrenal aldosterone and corticosterone synthesis was not expected. The concentration of aldosterone and corticosterone in the brain of intact rats derives primarily from the circulation (revised manuscript submitted). Adrenalectomy results in undetectable amount of aldosterone and corticosterone in plasma, and low, but consistently detectable amounts in the brain (revised manuscript submitted). The large amounts of aldosterone and corticosterone entering the brain from the circulation masks the small amounts produced in the brain and the effect of local inhibition by trilostane would not be detected by the methods available (12, 13) (revised manuscript submitted). An assay sensitive enough to measure differences in aldosterone synthesis in circumventricular organs by the icv trilostane treatment is not yet available. It is assumed from the physiological data available that the ratio of agonists (DOC and aldosterone) to antagonists (progesterone and corticosterone) at the level to the relevant brain mineralocorticoid receptors was too low to sustain the salt induced hypertension in these Dahl SS rats.
Progesterone treatment increases the espression of mineralocorticoid receptors in hippocampal neurons, but only after estrogen pretreatment (5) . An alternative explanation, that the trilostane-induced decrease in progesterone may have decreased the density of mineralocorticoid receptors in the circumventricular areas, is less plausible, than that of a decrease in mineralocorticoid receptor agonists, as the increase in mineralocorticoid receptor synthesis produced by progesterone requires previous exposure to estrogens and the anti-hypertensive effect of trilostane was seen in both males and females (5).
In conclusion, the brain is capable of the de novo synthesis of a small amount of adrenal corticosteroids from cholesterol. Unlike the adrenal, the brain produces very small amounts of DOC, the substrate for the aldosterone synthase and 11 -hydroxylase enzymes, in favor of other neurosteroids. The icv infusion of the 3 -hydroxysteroid dehydrogenase antagonist trilostane at a rate that is too low to completely inhibit the conversion of pregnenolone to progesterone prevented the increase in blood pressure and normalized the hypertension of two different cohorts of Dahl SS rats challenged with a high salt diet. These data support the hypothesis that synthesis of aldosterone in the circumventricular areas of the brain is part of the etiology of the hypertension in the Dahl SS/jr rat and that such synthesis may be part of normal blood pressure homeostasis. 
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